Research ArticleOriginal Research

The Impact of Increased Hydrocodone Regulation on Opioid Prescribing in an Urban Safety-Net Health Care System

Thomas F. Northrup, Kelley Carroll, Robert Suchting, Yolanda R. Villarreal, Mohammad Zare and Angela L. Stotts
The Journal of the American Board of Family Medicine May 2019, 32 (3) 362-374; DOI: https://doi.org/10.3122/jabfm.2019.03.180356

References

  1. 1.↵
    1. Rosenblum A,
    2. Marsch LA,
    3. Joseph H,
    4. Portenoy RK
    . Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol 2008;16:405–16.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Schuchat A,
    2. Houry D,
    3. Guy GP
    . New data on opioid use and prescribing in the United States. JAMA 2017;318:425–6.
    OpenUrlPubMed
  3. 3.↵
    1. Jones CM,
    2. Lurie PG,
    3. Throckmorton DC
    . Effect of US Drug Enforcement Administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Inter Med 2016;176:399–402.
    OpenUrl
  4. 4.↵
    1. Perry J,
    2. VanDenKerkhof EG,
    3. Wilson R,
    4. Tripp DA
    . Development of a guided internet-based psycho-education intervention using cognitive behavioral therapy and self-management for individuals with chronic pain. Pain Manag Nurs 2017;18:90–101.
    OpenUrl
  5. 5.↵
    United States Centers for Disease Control. Calculating total daily dose of opioids for safer dosage. 2018. Available from: https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf. Accessed January 22, 2018.
  6. 6.↵
    1. Liang Y,
    2. Turner BJ
    . Assessing risk for drug overdose in a national cohort: Role for both daily and total opioid dose? J Pain 2015;16:318–25.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Dunn KM,
    2. Saunders KW,
    3. Rutter CM,
    4. et al
    . Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010;152:85–92.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Gomes T,
    2. Mamdani MM,
    3. Dhalla IA,
    4. Paterson JM,
    5. Juurlink DN
    . Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171:686–91.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Rudd RA
    . Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morbid Mortal Wkly Rep 2016;65.
  10. 10.↵
    1. Edlund MJ,
    2. Martin BC,
    3. Russo JE,
    4. DeVries A,
    5. Braden JB,
    6. Sullivan MD
    . The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: The role of opioid prescription. Clin J Pain 2014;30:557–64.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration. The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. 2013. Available from: http://www.samhsa.gov/data/sites/default/files/DAWN127/DAWN127/sr127-DAWN-highlights.htm. Accessed January 19, 2018.
  12. 12.↵
    1. Miller M,
    2. Barber CW,
    3. Leatherman S,
    4. et al
    . Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015;175:608–15.
    OpenUrl
  13. 13.↵
    US Department of Justice Drug Enforcement Administration, Diversion Control Division. Rules—2014. 2014. Available from: https://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0822.htm. Accessed January 18, 2018.
  14. 14.↵
    United States Drug Enforcement Administration. Drug Scheduling. 2019. Available from: https://www.dea.gov/drug-scheduling. Accessed January 4, 2019.
  15. 15.↵
    1. Dowell D,
    2. Haegerich TM,
    3. Chou R
    . CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 2016;315:1624–45.
    OpenUrlCrossRefPubMed
  16. 16.↵
    United States Department of Health and Human Services, Centers for Disease Control. Opioid oral morphine milligram equivalent (MME) conversion factors. 2016. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-Aug-2017.pdf. Accessed January 22, 2018.
  17. 17.↵
    1. Carroll K,
    2. Northrup T,
    3. Zare M,
    4. Stotts A
    . Dramatic reduction in hydrocodone prescriptions in an urban safety net health care system: Has it improved patient safety or led to increased patient suffering? Pain Med 2016;17:213–6.
    OpenUrl
  18. 18.↵
    1. Das M,
    2. Jain R,
    3. Dhawan A,
    4. Kaur A
    . Assessment of abuse liability of Tramadol among experienced drug users: Double-blind crossover randomized controlled trial. J Opioid Manag 2016;12:421–30.
    OpenUrl
  19. 19.↵
    1. Jalali S,
    2. Thomas D,
    3. Shetty P,
    4. Cooper Jason C
    . Higher Regulatory Control of Tramadol to Prevent its Abuse and Dependence. J Drug Policy Analysis 2017. DOI: 10.1515/jdpa-2016–0008.
  20. 20.↵
    National Research Council. Relieving Pain in America: A Blueprint for Transforming Prevention, Care. Education, and Research. Washington, DC: The National Academies Press. 2011.
  21. 21.↵
    International Association for the Study of Pain. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986;3:S1–S226.
    OpenUrlPubMed
  22. 22.↵
    1. Lee JH,
    2. Herzog TA,
    3. Meade CD,
    4. Webb MS,
    5. Brandon TH
    . The use of GEE for analyzing longitudinal binomial data: A primer using data from a tobacco intervention. Addict Behav 2007;32:187–93.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Goodwin L,
    2. Gazard B,
    3. Aschan L,
    4. MacCrimmon S,
    5. Hotopf M,
    6. Hatch S
    . Taking an intersectional approach to define latent classes of socioeconomic status, ethnicity and migration status for psychiatric epidemiological research. Epidemiol Psychiatr Sci 2018;27:589–600.
    OpenUrl
  24. 24.↵
    1. Schild C,
    2. Reed EA,
    3. Hingston T,
    4. Dennis CH,
    5. Wilson AC
    . Neighborhood characteristics: Influences on pain and physical function in youth at risk for chronic pain. Children 2016;3:35.
    OpenUrl
  25. 25.↵
    1. Haynes A,
    2. Kleinschmidt K,
    3. Forrester MB,
    4. Young A
    . Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone. Clinical toxicology (Philadelphia, PA) 2016;54:434–40.
    OpenUrl
  26. 26.↵
    1. Bao Y,
    2. Pan Y,
    3. Taylor A,
    4. et al
    . Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff 2016;35:1045–51.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Hurstak EE,
    2. Kushel M,
    3. Chang J,
    4. et al
    . The risks of opioid treatment: Perspectives of primary care practitioners and patients from safety-net clinics. Subst Abuse 2017;38:213–21.
    OpenUrl
  28. 28.↵
    1. Jamison RN,
    2. Sheehan KA,
    3. Scanlan E,
    4. Matthews M,
    5. Ross EL
    . Beliefs and attitudes about opioid prescribing and chronic pain management: Survey of primary care providers. J Opioid Manag 2014;10:375–82.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Wiese HJC,
    2. Piercey RR,
    3. Clark CD
    . Changing prescribing behavior in the United States: Moving upstream in opioid prescription education. Clin Pharmacol Ther 2018;103:982–9.
    OpenUrl
  30. 30.↵
    1. Gwira Baumblatt JA,
    2. Wiedeman C,
    3. Dunn JR,
    4. Schaffner W,
    5. Paulozzi LJ,
    6. Jones TF
    . High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med 2014;174:796–801.
    OpenUrl
  31. 31.↵
    United States Centers for Disease Control. CDC grand rounds: Prescription drug overdoses—A U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012;61:10–3.
    OpenUrlPubMed
  32. 32.↵
    1. Singhal A,
    2. Tien YY,
    3. Hsia RY
    . Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. PLoS ONE 2016;11:e0159224.
    OpenUrl
  33. 33.↵
    1. Pletcher MJ,
    2. Kertesz SG,
    3. Kohn MA,
    4. Gonzales R
    . Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008;299:70–8.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Chen I,
    2. Kurz J,
    3. Pasanen M,
    4. et al
    . Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med 2005;20:593–8.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Burgess DJ,
    2. Nelson DB,
    3. Gravely AA,
    4. et al
    . Racial differences in prescription of opioid analgesics for chronic noncancer pain in a national sample of veterans. J Pain 2014;15:447–55.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Cerdá M,
    2. Ransome Y,
    3. Keyes KM,
    4. et al
    . Prescription opioid mortality trends in New York City, 1990–2006: Examining the emergence of an epidemic. Drug Alcohol Depend 2013;132(1–2):53–62.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Torres CA,
    2. Thorn BE,
    3. Kapoor S,
    4. DeMonte C
    . An examination of cultural values and pain management in foreign-born spanish-speaking hispanics seeking care at a federally qualified health center. Pain Med 2017;18:2058–69.
    OpenUrl
  38. 38.↵
    1. Fishbain DA,
    2. Cole B,
    3. Lewis J,
    4. Rosomoff HL,
    5. Rosomoff RS
    . What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9:444–59.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords